Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target
1 Followers
RYTM Analyst Ratings
Strong Buy
14Buy1Hold0Sell
Based on 15 analysts giving stock ratings to Rhythm Pharmaceuticals in the past 3 months
RYTM Stock 12 Month Forecast
Average Price Target
MXN 2,786.90â–˛(49.83% Upside)Based on 15 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is MXN 2,786.90 with a high forecast of MXN 3,836.48 and a low forecast of MXN 2,234.84. The average price target represents a 49.83% change from the last price of MXN 1,860.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighMXN 3.84K
AverageMXN 2.79K
LowMXN 2.23K
Highest Price TargetHighestMXN 3,836.48Average Price TargetMXN 2,786.90Lowest Price TargetLowestMXN 2,234.84
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Priyanka Grover | J.P. Morgan | MXN 2,700.44→MXN 2,644.57 | buy | 42.18%Upside | Reiterated | 11/06/26 | ||
| Samantha Semenkow | Citi | MXN 2,663.19 | buy | 43.18%Upside | Reiterated | 11/05/26 | ||
| Whitney Ijem | Canaccord Genuity | MXN 2,868.05→MXN 3,128.78 | buy | 68.21%Upside | Reiterated | 11/05/26 | ||
| Jonathan Wolleben | Citizens JMP | MXN 2,979.79→MXN 3,091.54 | buy | 66.21%Upside | Reiterated | 11/04/26 | ||
| Michael Ulz | Morgan Stanley | MXN 2,793.56→MXN 2,719.06 | buy | 46.19%Upside | Reiterated | 11/04/26 | ||
| Derek Archila | Wells Fargo | MXN 2,886.67 | buy | 55.20%Upside | Reiterated | 11/04/26 | ||
| Seamus Fernandez | Guggenheim | MXN 2,663.19→MXN 2,737.69 | buy | 47.19%Upside | Reiterated | 11/04/26 | ||
| Tazeen Ahmad | Bank of America Securities | MXN 2,793.56 | buy | 50.19%Upside | Reiterated | 11/03/26 | ||
| Lisa Walter | RBC Capital | MXN 2,961.17 | buy | 59.20%Upside | Reiterated | 11/03/26 | ||
| Phil Nadeau | TD Cowen | MXN 2,421.08 | buy | 30.17%Upside | Reiterated | 11/03/26 | ||
 Alethia YoungNot Ranked | William Blair | MXN 3,836.48 | buy | 106.26%Upside | Initiated | 10/15/26 | ||
| Ram Selvaraju | H.C. Wainwright | MXN 1,955.49→MXN 2,421.08 | buy | 30.17%Upside | Reiterated | 10/12/26 | ||
| Kalpit Patel | Wolfe Research | ― | buy | ― | Initiated | 09/17/26 | ||
| Basma Radwan | Leerink Partners | MXN 2,476.95 | buy | 33.17%Upside | Initiated | 09/14/26 | ||
| David Hoang | Deutsche Bank | MXN 2,234.84 | hold | 20.15%Upside | Initiated | 08/27/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Priyanka GroverJ.P. Morgan | BuyReiteratedMXN 2,700.44→MXN 2,644.57 | 11/06/26 | 42.18%Upside | ||
| Samantha SemenkowCiti | BuyReiteratedMXN 2,663.19 | 11/05/26 | 43.18%Upside | ||
| Whitney IjemCanaccord Genuity | BuyReiteratedMXN 2,868.05→MXN 3,128.78 | 11/05/26 | 68.21%Upside | ||
| Jonathan WollebenCitizens JMP | BuyReiteratedMXN 2,979.79→MXN 3,091.54 | 11/04/26 | 66.21%Upside | ||
| Michael UlzMorgan Stanley | BuyReiteratedMXN 2,793.56→MXN 2,719.06 | 11/04/26 | 46.19%Upside | ||
| Derek ArchilaWells Fargo | BuyReiteratedMXN 2,886.67 | 11/04/26 | 55.20%Upside | ||
| Seamus FernandezGuggenheim | BuyReiteratedMXN 2,663.19→MXN 2,737.69 | 11/04/26 | 47.19%Upside | ||
| Tazeen AhmadBank of America Securities | BuyReiteratedMXN 2,793.56 | 11/03/26 | 50.19%Upside | ||
| Lisa WalterRBC Capital | BuyReiteratedMXN 2,961.17 | 11/03/26 | 59.20%Upside | ||
| Phil NadeauTD Cowen | BuyReiteratedMXN 2,421.08 | 11/03/26 | 30.17%Upside | ||
| Alethia YoungWilliam BlairNot Ranked | BuyInitiatedMXN 3,836.48 | 10/15/26 | 106.26%Upside | ||
| Ram SelvarajuH.C. Wainwright | BuyReiteratedMXN 1,955.49→MXN 2,421.08 | 10/12/26 | 30.17%Upside | ||
| Kalpit PatelWolfe Research | BuyInitiated | 09/17/26 | ― | ||
| Basma RadwanLeerink Partners | BuyInitiatedMXN 2,476.95 | 09/14/26 | 33.17%Upside | ||
| David HoangDeutsche Bank | HoldInitiatedMXN 2,234.84 | 08/27/26 | 20.15%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Rhythm Pharmaceuticals
3 Months
Success Rate11/14 ratings generated profit
79%
Average Return
+7.88%
Copying Seamus Fernandez's trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +7.88% per trade.
1 Year
Success Rate37/38 ratings generated profit
97%
Average Return
+72.17%
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 97.37% of your transactions generating a profit, with an average return of +72.17% per trade.
2 Years
Success Rate37/38 ratings generated profit
97%
Average Return
+163.38%
Copying Joseph Stringer's trades and holding each position for 2 Years would result in 97.37% of your transactions generating a profit, with an average return of +163.38% per trade.
RYTM Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 1 | 7 | 11 |
| Buy | 22 | 22 | 20 | 17 | 11 |
| Hold | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 30 | 29 | 22 | 25 | 22 |
In the current month, RYTM has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RYTM average Analyst price target in the past 3 months is 2,786.90.
RYTM Financial Forecast
HighMXN -3.72
ConsensusMXN -45.94
LowMXN -106.38
RYTM Earnings Forecast
Next quarter’s earnings estimate for RYTM is -MXN 45.94 with a range of -MXN 106.38 to -MXN 3.72. The previous quarter’s EPS was -MXN 11.36. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 2.72B
ConsensusMXN 2.04B
LowMXN 1.83B
RYTM Sales Forecast
Next quarter’s sales forecast for RYTM is MXN 2.04B with a range of MXN 1.83B to MXN 2.72B. The previous quarter’s sales results were MXN 1.72B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
RYTM Stock Forecast FAQ
What is MX:RYTM’s average 12-month price target, according to analysts?
Based on analyst ratings, Rhythm Pharmaceuticals’s 12-month average price target is Mex$2,786.90.
What is MX:RYTM’s upside potential, based on the analysts’ average price target?
Rhythm Pharmaceuticals has 49.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Rhythm Pharmaceuticals a Buy, Sell or Hold?
Rhythm Pharmaceuticals has a consensus rating of Strong Buy, which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
What is Rhythm Pharmaceuticals’s share price target?
The average share price target for Rhythm Pharmaceuticals is Mex$2,786.90. This is based on 15 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$3,836.48, and the lowest forecast is Mex$2,234.84. The average share price target represents a 49.83% increase from the current price of Mex$1,860.
What do analysts say about Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Street analysts.
How can I buy shares of Rhythm Pharmaceuticals?
To buy shares of MX:RYTM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
